WordNet

reason or establish by induction
cause to arise; "induce a crisis" (同)bring_on
produce electric current by electrostatic or magnetic processes (同)induct
cause to do; cause to act in a specified manner; "The ads induced me to buy a VCR"; "My children finally got me to buy a computer"; "My wife made me buy a new sofa" (同)stimulate, cause, have, get, make
cause to occur rapidly; "the infection precipitated a high fever and allergic reactions" (同)stimulate, rush, hasten
use recreational drugs (同)do drugs
administer a drug to; "They drugged the kidnapped tourist" (同)dose
a substance that is used as a medicine or narcotic
brought about or caused; not spontaneous; "a case of steroid-induced weakness"
a disorder of lipid metabolism; abnormal levels of certain fats accumulate in the body

PrepTutorEJDIC

〈人〉‘に'『勧めて』(…)『させる』 / …‘を'『引き起こす』,もたらす(cause) / 〈電気〉‘を'誘導する / …‘を'帰納する
『薬』,薬品,薬剤 / 『麻薬』,麻酔剤 / 〈人〉‘に'薬(特に麻酔剤)を与える / 〈飲食物〉‘に'(麻酔薬・毒薬などの)薬を混ぜる

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

1. 薬物アレルギー患者へのアプローチ an approach to the patient with drug allergy
2. 心血管系剤によって誘発された肺疾患 pulmonary disease induced by cardiovascular drugs
3. 薬物アレルギー：分類および臨床的特徴 drug allergy classification and clinical features
4. 抗マラリア剤：概要 antimalarial drugs an overview
5. 薬剤性血小板減少症 drug induced thrombocytopenia

English Journal

In silico modeling to predict drug-induced phospholipidosis.

Choi SS, Kim JS, Valerio LG Jr, Sadrieh N.Author information Science and Research Staff, Office of Pharmaceutical Science, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, 10903 New Hampshire Avenue, Silver Spring, MD 20993-0002, USA.AbstractDrug-induced phospholipidosis (DIPL) is a preclinical finding during pharmaceutical drug development that has implications on the course of drug development and regulatory safety review. A principal characteristic of drugs inducing DIPL is known to be a cationic amphiphilic structure. This provides evidence for a structure-based explanation and opportunity to analyze properties and structures of drugs with the histopathologic findings for DIPL. In previous work from the FDA, in silico quantitative structure-activity relationship (QSAR) modeling using machine learning approaches has shown promise with a large dataset of drugs but included unconfirmed data as well. In this study, we report the construction and validation of a battery of complementary in silico QSAR models using the FDA's updated database on phospholipidosis, new algorithms and predictive technologies, and in particular, we address high performance with a high-confidence dataset. The results of our modeling for DIPL include rigorous external validation tests showing 80-81% concordance. Furthermore, the predictive performance characteristics include models with high sensitivity and specificity, in most cases above ≥80% leading to desired high negative and positive predictivity. These models are intended to be utilized for regulatory toxicology applied science needs in screening new drugs for DIPL.
Toxicology and applied pharmacology.Toxicol Appl Pharmacol.2013 Jun 1;269(2):195-204. doi: 10.1016/j.taap.2013.03.010. Epub 2013 Mar 27.
Drug-induced phospholipidosis (DIPL) is a preclinical finding during pharmaceutical drug development that has implications on the course of drug development and regulatory safety review. A principal characteristic of drugs inducing DIPL is known to be a cationic amphiphilic structure. This provides
PMID 23541745

Drug induced phospholipidosis: an acquired lysosomal storage disorder.

Shayman JA, Abe A.Author information Department of Internal Medicine, University of Michigan Medical School, University of Michigan, Ann Arbor, MI 48109, USA. jshayman@umich.eduAbstractThere is a strong association between lysosome enzyme deficiencies and monogenic disorders resulting in lysosomal storage disease. Of the more than 75 characterized lysosomal proteins, two thirds are directly linked to inherited diseases of metabolism. Only one lysosomal storage disease, Niemann-Pick disease, is associated with impaired phospholipid metabolism. However, other phospholipases are found in the lysosome but remain poorly characterized. A recent exception is lysosomal phospholipase A2 (group XV phospholipase A2). Although no inherited disorder of lysosomal phospholipid metabolism has yet been associated with a loss of function of this lipase, this enzyme may be a target for an acquired form of lysosomal storage, drug induced phospholipidosis. This article is part of a Special Issue entitled Phospholipids and Phospholipid Metabolism.
Biochimica et biophysica acta.Biochim Biophys Acta.2013 Mar;1831(3):602-11. doi: 10.1016/j.bbalip.2012.08.013. Epub 2012 Aug 30.
There is a strong association between lysosome enzyme deficiencies and monogenic disorders resulting in lysosomal storage disease. Of the more than 75 characterized lysosomal proteins, two thirds are directly linked to inherited diseases of metabolism. Only one lysosomal storage disease, Niemann-Pic
PMID 22960355

Comparison of urinary and serum levels of di-22:6-bis(monoacylglycerol)phosphate as noninvasive biomarkers of phospholipidosis in rats.

Thompson KL, Zhang J, Stewart S, Rosenzweig BA, Shea K, Mans D, Colatsky T.Author information Division of Drug Safety Research, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD 20993, USA. Karol.thompson@fda.hhs.govAbstractPhospholipidosis (PLD), an abnormal accumulation of phospholipids within tissues, is observed during the preclinical testing of many pharmaceutical drugs. Diagnosis of PLD is currently based on morphologic criteria. An understanding of the clinical incidence of PLD and its possible relationship to adverse drug reactions has been hampered by the absence of noninvasive biomarkers for PLD. The uncommon phospholipid di-docosahexaenoyl bis(monoacylglycerol) phosphate (di-22:6-BMP) has been proposed as a potential urinary biomarker for PLD, but data on the utility of serum di-22:6-BMP measurements in diagnosing PLD is more limited. In this report, we compared the performance of serum and urinary di-22:6-BMP as biomarkers for PLD in rats treated with the PLD-inducing drugs amiodarone and 4,4'-diethylaminoethoxyhexestrol dihydrochloride or the hepatotoxicant acetaminophen (APAP). Serum levels of di-22:6-BMP showed a higher correlation to a generalized PLD incidence score than did levels in urine, but were unexpectedly elevated in rats with marked levels of APAP-induced liver necrosis. When samples were filtered based on serum ALT or liver histopathology thresholds, the diagnostic accuracy of serum di-22:6-BMP for PLD improved to the high level observed for urinary di-22:6-BMP without sample exclusion. These data help define the potential context-of-use of serum di-22:6-BMP as a non-clinical biomarker of PLD.
Toxicology letters.Toxicol Lett.2012 Sep 3;213(2):285-91. doi: 10.1016/j.toxlet.2012.07.013. Epub 2012 Jul 22.
Phospholipidosis (PLD), an abnormal accumulation of phospholipids within tissues, is observed during the preclinical testing of many pharmaceutical drugs. Diagnosis of PLD is currently based on morphologic criteria. An understanding of the clinical incidence of PLD and its possible relationship to a
PMID 22828012

Japanese Journal

In vitro screening system for drug-induced lipidosis using lymphocyte culture.(GENERAL SESSION BY POSTER PRESENTATION)(ACTIVE OXYGEN ETC)

KOSEKI NAOTERU,MIYAWAKI IZURU,HORIE HIROSHI,KOJITANI TAKATOSHI,AOKI YASUHIRO,YASUBA MASASHI
Journal of toxicological sciences 27(4), 385, 2002-10
NAID 110001802827